Artificial intelligence (AI) is not only boosting the business for tech companies. Healthcare and biotech industries are also ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST Salt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

What's the best next use of artificial intelligence (AI)? Plenty of people would say drug development. And they'd arguably be right. That's not something for down the road, though, when AI is more ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

RXRX acquired Rallybio's full stake in the joint HPP program, including REV102 and a backup molecule. The deal allows RXRX to accelerate the development of REV102 using its Recursion OS AI platform ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a clinical-stage biotech company that uses AI and ML to develop novel therapeutics. The company’s AI-driven drug discovery platform is called the ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best mid cap stocks to buy according to hedge funds. On November 1, TD Cowen analyst Brendan Smith touted the progress the company has made ...

Bank of America Securities 2023 Health Care Conference – May 9 through May 11, 2023 18th Annual Needham Technology & Media Conference – May 16 through May 18, 2023 Morgan Stanley Sustainable Finance ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...